01.12.2017 | Research article | Ausgabe 1/2017 Open Access

Cytotoxicity of replication-competent adenoviruses powered by an exogenous regulatory region is not linearly correlated with the viral infectivity/gene expression or with the E1A-activating ability but is associated with the p53 genotypes
- Zeitschrift:
- BMC Cancer > Ausgabe 1/2017
Electronic supplementary material
Background
Methods
Cells
Construction of ad
Cytotoxicity of ad
Ad infectivity/ad-mediated gene expression
Expression of ad receptor molecules
Transcriptional activity
Western blot analysis
Results
Cytotoxicity of replication-competent Ad5 and AdF35
Cells
|
IC
50 values (Average ± SE)
|
|||||
---|---|---|---|---|---|---|
Ad5/MK
|
AdF35/MK
|
Ad5/Sur
|
AdF35/Sur
|
Ad5/COX-2
|
AdF35/COX-2
|
|
Pancreatic carcinoma (1 × 10
3 vp/cell)
|
||||||
AsPC-1
|
16.1 ± 2.7
|
9.2 ± 0.6
|
15.7 ± 0.5
|
3.6 ± 0.6
|
245 ± 41.5
|
38.8 ± 12.7
|
PANC-1
|
36.1 ± 8.8
|
13.7 ± 6.4
|
15.9 ± 2.6
|
2.6 ± 0.2
|
244 ± 77.1
|
27.6 ± 0.6
|
BxPC-3
|
44.6 ± 3.1
|
4.1 ± 2.0
|
64.9 ± 8.8
|
1.8 ± 0.9
|
474 ± 9.6
|
37.1 ± 7.1
|
MIA-PaCa-2
|
12.5 ± 2.7
|
2.2 ± 0.3
|
105 ± 16.3
|
8.0 ± 0.9
|
69.6 ± 5.4
|
32.1 ± 6.2
|
Esophageal carcinoma (1 × 10
4 vp/cell)
|
||||||
TE-1
|
32.2 ± 2.4
|
10.1 ± 2.0
|
56.0 ± 1.5
|
9.71 ± 4.7
|
317 ± 96.5
|
18.5 ± 1.9
|
TE-2
|
244 ± 188
|
28.6 ± 4.6
|
100 ± 32.6
|
15.1 ± 3.9
|
62.8 ± 19.9
|
46.6 ± 22.3
|
TE-10
|
2.6 ± 1.1
|
12.3 ± 4.7
|
27.3 ± 8.6
|
3.7 ± 0.6
|
46.1 ± 6.3
|
8.1 ± 1.6
|
TE-11
|
1.5 ± 0.3
|
3.0 ± 0.5
|
1.5 ± 0.3
|
1.1 ± 0.5
|
30.9 ± 11.8
|
7.7 ± 1.6
|
YES-2
|
5.7 ± 2.4
|
0.3 ± 0.2
|
7.6 ± 1.7
|
1.4 ± 0.6
|
80.1 ± 18.7
|
4.0 ± 2.7
|
YES-4
|
1.2 ± 0.8
|
10.6 ± 1.6
|
2.1 ± 0.3
|
7.1 ± 2.8
|
18.8 ± 4.7
|
5.6 ± 1.0
|
YES-5
|
16.7 ± 6.3
|
1.5 ± 1.0
|
8.1 ± 3.1
|
5.8 ± 1.9
|
37.5 ± 7.8
|
16.8 ± 5.3
|
YES-6
|
424 ± 85.2
|
157 ± 40.9
|
89.5 ± 21.5
|
226 ± 14.5
|
260 ± 43.1
|
40 ± 1.9
|
T.Tn
|
9.6 ± 0.9
|
1.0 ± 0.2
|
36.1 ± 1.2
|
1.1 ± 0.0
|
58.2 ± 19.0
|
6.0 ± 0.7
|
Mesothelioma (1 × 10
3 vp/cell)
|
||||||
NCI-H2452
|
7.18 ± 1.0
|
18.2 ± 6.2
|
43.1 ± 2.9
|
27.2 ± 9.0
|
41.6 ± 11.7
|
50.8 ± 5.8
|
NCI-H2052
|
520.6 ± 14.8
|
143.2 ± 24.8
|
516.1 ± 11.3
|
187.2 ± 50.9
|
>1000
|
524.0 ± 18.1
|
NCI-H226
|
35.1 ± 3.5
|
59.3 ± 0.6
|
55.5 ± 1.1
|
55.7 ± 2.5
|
550.0 ± 10.0
|
531.3 ± 11.3
|
NCI-H28
|
4.4 ± 0.4
|
5.6 ± 0.1
|
45.9 ± 21.1
|
7.1 ± 0.1
|
140.3 ± 23.7
|
36.6 ± 2.1
|
MSTO-211H
|
12.6 ± 2.2
|
0.7 ± 0.0
|
95.0 ± 19.1
|
3.9 ± 0.2
|
450.6 ± 17.2
|
10.9 ± 2.0
|
Correlation of ad infectivity and receptor
Infectivity tested at MOI = 30
|
Receptor expression
|
|||
---|---|---|---|---|
Cells
|
Ad5/GFP
|
AdF35/GFP
|
CAR
|
CD46
|
(% positive cells
a)
|
(% mean fluorescence intensity
b)
|
|||
Pancreatic carcinoma
|
||||
HEK293
|
98.98 ± 0.11
|
99.47 ± 0.11
|
100
|
100
|
AsPC-1
|
8.47 ± 0.27
|
25.32 ± 0.57
|
71.6
|
182.4
|
PANC-1
|
7.66 ± 0.50
|
28.35 ± 0.41
|
65.5
|
175.7
|
BxPC-3
|
19.48 ± 0.62
|
68.95 ± 0.45
|
26.8
|
231.1
|
MIA-PaCa-2
|
5.89 ± 0.54
|
65.41 ± 0.68
|
2.0
|
62.6
|
Esophageal carcinoma
|
||||
HEK293
|
87.20±0.52
|
78.05±0.70
|
100
|
100
|
TE-1
|
8.06±1.17
|
53.47±0.10
|
11.5
|
321.5
|
TE-2
|
0.79±0.14
|
10.15±0.44
|
33.7
|
160.2
|
TE-10
|
16.15±0.52
|
35.33±0.67
|
25.9
|
99.7
|
TE-11
|
22.86±0.53
|
42.82±0.74
|
39.1
|
290.2
|
YES-2
|
5.09±1.29
|
51.54±0.36
|
0.3
|
131.7
|
YES-4
|
27.18±0.16
|
61.23±0.07
|
47.2
|
135.2
|
YES-5
|
22.18±0.32
|
69.97±0.89
|
27.0
|
176.3
|
YES-6
|
16.59±0.25
|
27.63±0.17
|
53.1
|
120.4
|
T.Tn
|
0.49±1.00
|
21.60±0.15
|
14.3
|
208.9
|
Mesothelioma
|
||||
HEK293
|
93.7±0.1
|
93.8±0.4
|
100
|
100
|
NCI-H2452
|
49.8±0.3
|
75.3±0.6
|
35.6
|
117.6
|
NCI-H2052
|
7.4±0.3
|
81.5±0.5
|
0.7
|
174.7
|
NCI-H226
|
78.5±1.2
|
81.9±1.5
|
84.0
|
164.7
|
NCI-H28
|
85.5±0.4
|
95.1±0.2
|
17.8
|
150.4
|
MSTO-211H
|
8.7±0.3
|
67.9±0.9
|
2.3
|
56.0
|
Tumor type
|
Infectivity
|
Receptor expression
|
Correlation
|
P value
|
---|---|---|---|---|
(% positive cells)
|
(% mean fluorescence intensity)
|
coefficient
|
||
Pancreatic carcinoma
|
||||
Ad5/GFP
|
CAR
|
−0.13
|
0.87
|
|
AdF35/GFP
|
CD46
|
−0.20
|
0.80
|
|
Esophageal carcinoma
|
||||
Ad5/GFP
|
CAR
|
0.62
|
0.07
|
|
AdF35/GFP
|
CD46
|
0.14
|
0.71
|
|
Mesothelioma
|
||||
Ad5/GFP
|
CAR
|
0.68
|
0.21
|
|
AdF35/GFP
|
CD46
|
0.72
|
0.16
|
Correlation of ad infectivity and ad-mediated cytotoxicity
Tumor type
|
Infectivity
b
|
Correlation coefficient
|
P value
|
---|---|---|---|
Ad-mediated cytotoxicity
a
|
|||
Pancreatic carcinoma
|
|||
Ad5/MK
|
Ad5/GFP
|
0.77
|
0.22
|
Ad5/Sur
|
Ad5/GFP
|
0.05
|
0.95
|
Ad5/COX-2
|
Ad5/GFP
|
0.94
|
0.06
|
AdF35/MK
|
AdF35/GFP
|
−0.89
|
0.11
|
AdF35/Sur
|
AdF35/GFP
|
0.31
|
0.69
|
AdF35/COX-2
|
AdF35/GFP
|
0.14
|
0.86
|
Esophageal carcinoma
|
|||
Ad5/MK
|
Ad5/GFP
|
−0.15
|
0.70
|
Ad5/Sur
|
Ad5/GFP
|
−0.52
|
0.15
|
Ad5/COX-2
|
Ad5/GFP
|
−0.22
|
0.56
|
AdF35/MK
|
AdF35/GFP
|
−0.36
|
0.34
|
AdF35/Sur
|
AdF35/GFP
|
−0.28
|
0.47
|
AdF35/COX-2
|
AdF35/GFP
|
−0.53
|
0.13
|
Mesothelioma
|
|||
Ad5/MK
|
Ad5/GFP
|
−0.57
|
0.31
|
Ad5/Sur
|
Ad5/GFP
|
−0.65
|
0.24
|
Ad5/COX-2
|
Ad5/GFP
|
−0.18
|
0.82
|
AdF35/MK
|
AdF35/GFP
|
0.10
|
0.87
|
AdF35/Sur
|
AdF35/GFP
|
0.07
|
0.91
|
AdF35/COX-2
|
AdF35/GFP
|
0.15
|
0.82
|
Correlation of transcriptional activity for E1 activation and ad-mediated cytotoxicity
Transcriptional activity (% activity of SV40 T antigen)
|
|||
---|---|---|---|
Cells
|
MK
|
Sur
|
COX-2
|
Pancreatic carcinoma
|
|||
AsPC-1
|
345 ± 59.9
|
75.6 ± 2.9
|
212 ± 11.5
|
PANC-1
|
224 ± 3.6
|
69.8 ± 4.28
|
243 ± 11.4
|
BxPC-3
|
454 ± 49.1
|
67.8 ± 10.6
|
363 ± 86.5
|
MIA-PaCa-2
|
182 ± 22.4
|
135 ± 7.0
|
783 ± 27.6
|
Esophageal carcinoma
|
|||
TE-1
|
400 ± 99.0
|
162 ± 13.6
|
752 ± 71.9
|
TE-2
|
375 ± 7.9
|
610 ± 136.5
|
625 ± 28.1
|
TE-10
|
339 ± 26.9
|
906 ± 34.9
|
431 ± 59.5
|
TE-11
|
702 ± 30.2
|
6770 ± 526.0
|
410 ± 128.0
|
YES-2
|
314 ± 20.2
|
1790 ± 156.0
|
351 ± 27.1
|
YES-4
|
187 ± 2.6
|
310 ± 13.2
|
282 ± 18.5
|
YES-5
|
745 ± 47.7
|
395 ± 11.2
|
160 ± 12.5
|
YES-6
|
540 ± 7.4
|
3110 ± 96.8
|
417 ± 31.4
|
T.Tn
|
199 ± 32.0
|
2410 ± 233.0
|
126 ± 10.2
|
Mesothelioma
|
|||
NCI-H2452
|
153 ± 45.7
|
35.0 ± 5.0
|
291 ± 72.4
|
NCI-H2052
|
189 ± 4.5
|
38.6 ± 1.0
|
233 ± 10.1
|
NCI-H226
|
112 ± 4.2
|
7.2 ± 0.3
|
381 ± 61.2
|
NCI-H28
|
348 ± 68.2
|
173 ± 62.1
|
250 ± 38.2
|
MSTO-211H
|
168 ± 18.4
|
134 ± 7.3
|
141 ± 14.0
|
Tumor type
|
Transcriptional
|
Correlation coefficient
|
P value
|
---|---|---|---|
Ad-mediated cytotoxicity
a
|
activity
b
|
||
Pancreatic carcinoma
|
|||
Ad5/MK
|
MK
|
0.57
|
0.43
|
Ad5/Sur
|
Sur
|
0.80
|
0.20
|
Ad5/COX-2
|
COX-2
|
−0.58
|
0.42
|
AdF35/MK
|
MK
|
−0.16
|
0.84
|
AdF35/Sur
|
Sur
|
0.99
|
0.01
c
|
AdF35/COX-2
|
COX-2
|
−0.18
|
0.81
|
Esophageal carcinoma
|
|||
Ad5/MK
|
MK
|
0.17
|
0.67
|
Ad5/Sur
|
Sur
|
−0.18
|
0.65
|
Ad5/COX-2
|
COX-2
|
0.60
|
0.09
|
AdF35/MK
|
MK
|
0.18
|
0.65
|
AdF35/Sur
|
Sur
|
0.19
|
0.62
|
AdF35/COX-2
|
COX-2
|
0.48
|
0.19
|
Mesothelioma
|
|||
Ad5/MK
|
MK
|
−0.07
|
0.92
|
AdF35/Sur
|
Sur
|
−0.27
|
0.66
|
Ad5/COX-2
|
COX-2
|
0.08
|
0.92
|
AdF35/MK
|
MK
|
−0.25
|
0.68
|
Ad5/Sur
|
Sur
|
−0.53
|
0.36
|
AdF35/COX-2
|
COX-2
|
0.54
|
0.35
|